Asset Details
Do you wish to reserve the book?
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Do you wish to request the book?
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
2009
Overview
Can combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, produce durable clinical responses in patients with cancer?
Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biomedical and Life Sciences
/ Biphenyl Compounds - pharmacology
/ Control
/ Fusion Proteins, bcr-abl - antagonists & inhibitors
/ Humans
/ progress
/ Protein Kinase Inhibitors - pharmacology
/ Proto-Oncogene Proteins c-bcl-2 - analysis
/ Proto-Oncogene Proteins c-bcl-2 - physiology
/ Tumors
